Syndecan-1/CD138 Antibody (359103) [Alexa Fluor™ Plus 488]

• Reactivity: Hu
• Clone: 359103
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 488

Syndecan-1/CD138 Antibody (359103) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects human Syndecan-1 in direct ELISAs. In direct ELISAs, this antibody shows approximately 60% cross-reactivity with recombinant mouse (rm) Syndecan‑1 and no cross-reactivity with recombinant human (rh) Syndecan-2, rhSyndecan-3, or rmSyndecan-4.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Syndecan-1/CD138 Antibody (359103) [Alexa Fluor™ Plus 488]

• CD138 antigen
• CD138
• SDC
• SDC1
• SYND1heparan sulfate proteoglycan fibroblast growth factor receptor
• syndecan 1
• syndecan proteoglycan 1
• syndecan
• Syndecan1
• Syndecan-1

Background

Syndecan-1, designated CD138, is a dimeric type I transmembrane (TM) protein that belongs to the syndecan family of Type 1 transmembrane proteins (1, 2). The four syndecan family members are major carriers of heparan sulfate (HS) and chondroitin sulfate glycosaminoglycans (GAGs) that have different expression patterns and extracellular sequences. Syndecan-1 forms weak non-covalent homodimers, or heterodimers with Syndecan-2 or -3, through interactions of the transmembrane domain (3). It is synthesized as a 310 amino acid (aa) precursor with a 17 aa signal sequence, a 234 aa extracellular domain (ECD) that includes three closely-spaced consensus Ser-Gly HS attachment sites near the N-terminus, a 25 aa TM segment, and a 34 aa cytoplasmic region that includes a PDZ binding motif with a tyrosine phosphorylation site. The ECD is variably modified by GAGs, producing molecular weights of 120-200 kDa for native Syndecan-1. Soluble forms are shed via proteolytic cleavage. Human Syndecan-1 ECD shares 65-71% aa identity with the ECD of rat, mouse, canine, equine and bovine Syndecan-1. Syndecan-1 shows highest expression on epithelial cells such as keratinocytes, and terminally differentiated B cells such as plasma cells (4, 5). It aids wound healing in skin, cornea, and heart following myocardial infarction by promoting re-epithelialization, migration, and collagen deposition (4-8). It binds chemokines, creating chemotactic gradients when shed, but also binds and modulates integrins to control the influx of leukocytes (5, 7, 9). The net effect is to allow, but limit, inflammation. In myeloma and other cancers, shedding of Syndecan-1 can facilitate growth, angiogenesis and metastasis (10-12). Growth factors, such as FGFs and HGF, bind GAG chains and use Syndecan-1 as a coreceptor (12, 13). The GAG chains may also be used by a variety of viruses and bacteria for cell adhesion and uptake (4).

1. Tkachenko, E. et al. (2005) Circ. Res. 96:488.
2. Mali, M. et al. (1990) J. Biol. Chem. 265:6884.
3. Dews, I.C. and K.R. MacKenzie (2007) Proc. Natl. Acad. Sci. USA 104:20782.
4. Fears, C.Y. and A. Woods (2006) Matrix Biol. 25:443.
5. Stepp, M.A. et al. (2002) J. Cell Sci. 115:4517.
6. Ojeh, N. et al. (2008) J. Invest. Dermatol. 128:26.
7. Stepp, M.A. et al. (2007) J. Cell Sci. 120:2851.
8. Vanhoutte, D. et al. (2007) Circulation 115:475.
9. Li, Q. et al. (2002) Cell 111:635.
10. Beauvais, D.M. et al. (2009) J. Exp. Med. 206:691.
11. Yang, Y. et al. (2007) J. Biol. Chem. 282:13326.
12. Derksen, P.W.B. et al. (2002) Blood 99:1405.
13. Su, G. et al. (2007) J. Biol. Chem. 282:14906.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.